Combination of Lenalidomide and Rituximab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) as Initial Treatment or Subsequent Therapy
The goal of this clinical research study is to learn if the combination of lenalidomide and rituximab can help to control CLL. The safety of this drug combination will also be studied. Lenalidomide is designed to change the body's immune system. It may also interfere with the development of tiny blood vessels that help support tumor growth. This may decrease the growth of cancer cells. Rituximab is designed to attach to cancer cells and damage them, which may cause the cells to die.
Treatment Location: N/A
The primary objective is to evaluate the efficacy of the combination of lenalidomide and rituximab in patients with chronic lymphocytic leukemia that have received prior therapy and in patients with chronic lymphocytic leukemia that have not been previously treated and are 65 years of age or older. The secondary objective of this study is safety of this combination. The third objective will be response according to disease characteristics, such as IgVH mutation status, FISH hierarchy and other translational research markers.
IRB Review and Approval Date: 12/12/2011
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: